Daily Stock Analysis, IDXG, Interpace Diagnostics Group Inc, priceseries

Interpace Diagnostics Group, Inc. provides commercialization services to biopharmaceutical companies. It focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for patient diagnosis and management. The company offers commercialized molecular tests which include PancraGen, ThyGenX, and ThyraMIR. PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment’s services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.